Follistatin is a binding protein involved in signaling that includes activin and myostatin. Follistatin-based gene therapy, purified proteins, and products marketed as “follistatin peptides” are different interventions. Evidence from one cannot establish the effects of another.[1][2]
- Class
- Binding protein
- Human example
- Small gene-transfer study
- Key limit
- Formulation is not interchangeable
What does follistatin do?
Follistatin can bind signaling proteins and interfere with their activity. Foundational experiments demonstrated antagonism of myostatin and increased muscle mass in transgenic mice. That work established a biological rationale, rather than a consumer treatment.[1]
When reading a claim, ask which follistatin form was used, what other ligands it affects, and how it was delivered. “Targets myostatin” alone leaves these important details unanswered.
What has been studied in people?
A small study published in 2015 used an AAV gene-transfer intervention expressing FS344 in six people with Becker muscular dystrophy. Four improved their six-minute walk distance and two did not. The authors described a proof-of-principle clinical study.[2]
The research question concerned a specific gene-delivery strategy in a defined disease. It did not test a retail vial bought online. Changing the formulation or delivery system creates a new question that needs its own evidence.
Why does the formulation matter?
A gene-transfer construct instructs cells to produce a protein. Giving a protein preparation is a different exposure. The duration, location, amount, and biological activity need not match. A shared name does not demonstrate equivalence.
| Label | What to verify |
|---|---|
| Follistatin protein | The exact form, identity, and biological activity |
| Follistatin gene therapy | The gene construct, delivery system, and studied population |
| “Follistatin peptide” listing | Whether a human trial actually tested that specific preparation |
How should you evaluate a follistatin claim?
Locate the original study before accepting a result. Identify whether its participants were people, animals, or laboratory cells. Then check whether the proposed product and the studied intervention are genuinely the same.
A detailed explanation of a pathway is useful background, but it does not replace a controlled human study. See the research-quality checklist for a structured way to assess the gap.
Questions, answered.
Is FS344 gene therapy the same as a follistatin injection?
No. A gene-transfer intervention and a protein preparation use different delivery strategies. The cited gene-therapy study cannot be treated as a trial of a marketplace vial.
Does “naturally occurring” mean risk-free?
No. A substance’s natural presence does not establish the safety of a particular preparation, exposure, or intended use.
Sources & further reading
Primary research and official records used for this page. Study results apply to the populations and interventions described.
- Regulation of myostatin activity and muscle growthLee & McPherron · PNAS · 2001 · Mechanistic and animal research
- A phase 1/2a follistatin gene therapy trial for Becker muscular dystrophyMendell et al. · Molecular Therapy · 2015 · Small gene-transfer study